Academic Journals Database
Disseminating quality controlled scientific knowledge

Experience of ramipril (Hartil) usage in patients with high cardiovascular risk (the OPTIMIST study

Author(s): I.A. Velizhanina | L.I. Gapon | E.S. Velizhanina | M.I. Shupina | A.V. Rudakov | T.S. Bondarenko

Journal: Racionalʹnaâ Farmakoterapiâ v Kardiologii
ISSN 1819-6446

Volume: 5;
Issue: 6;
Start page: 13;
Date: 2009;
Original page

Keywords: arterial hypertension | cardiovascular risk | ramipril.

Aim. To evaluate efficacy and safety of ramipril (Hartil, Egis) in treatment of patients with different cardiovascular risk (according to arterial hypertension (HT) risk stratification) in real clinical practice.Material and methods. 998 patients (424 men and 574 women; aged 57,4Ѓ}0,4 y.o.) with HT; with combination of HT and ischemic heart disease; with ischemic heart disease and high normal blood pressure (BP) were included in the open non-control non-comparative multicenter phase IV study. The anamnesis data collection, physical examination, evaluation of risk factors, the target organ damage, the associated cardiovascular diseases, total cardiovascular risk, previous therapy, and also BP measurement were performed.All patients received ramipril within 8 weeks additionally to previous antihypertensive therapy. The BP measurement was performed initially, after 4 and 8 weeks of therapy. Achievement of target BP level (BP
Why do you need a reservation system?      Save time & money - Smart Internet Solutions